HFB-301001 is under clinical development by HiFiBiO Therapeutics and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I drugs for Hepatocellular Carcinoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HFB-301001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HFB-301001 overview

HFB-301001 is under development for the treatment of solid tumors, soft tissue sarcoma, renal cell carcinoma, uterine carcinosarcoma, hepatocellular carcinoma and head and neck squamous cell carcinoma. It is administered through intravenous route. The drug candidate acts by targeting OX40 receptor and is developed based on drug intelligent science (DIS) platform.

HiFiBiO Therapeutics overview

HiFiBiO Therapeutics, a biotechnology company that engaged in providing antibody drug discovery services. The company is headquartered in United States.

For a complete picture of HFB-301001’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.